Your Article Summary
See Latest ArticlesZaBeCors Investigational New Drug Application Approved by the FDA
Corporate News Releases - The Healthcare Sales & Marketing Network, 11/20/08
ZaBeCor Pharmaceuticals announces that the United States Food and Drug Administration ("FDA") has approved the Company's Investigational New Drug Application ("IND") for the treatment of asthma. This approval enables the Company to proceed with Phase I clinical trials in humans for its asthma drug candidate, Excellair. The IND review included ZaBeCor's clinical development plan, Phase I clinical trial protocols, manufacturing plans and extensive pre-clinical studies.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Eslicarbazepine: A novel antiepileptic agent designed for improved efficacy and safety
Formulary , 12/16/09
Human genome sciences announces submission of marketing authorization application to emea for joulferon
Human Genome Sciences, 12/16/09
Mylan Receives Approval for Generic Version of Antiepileptic Keppra 1000 mg
Mylan, 12/15/09